Ian Robert Hardcastle
Ian Robert Hardcastle
Verified email at
Cited by
Cited by
Identification of a highly potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (NU7441) by screening of chromenone libraries
JJJ Leahy, BT Golding, RJ Griffin, IR Hardcastle, C Richardson, ...
Bioorganic & medicinal chemistry letters 14 (24), 6083-6087, 2004
Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor
TG Davies, J Bentley, CE Arris, FT Boyle, NJ Curtin, JA Endicott, ...
Nature structural biology 9 (10), 745-749, 2002
Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach
IR Hardcastle, X Cockcroft, NJ Curtin, MD El-Murr, JJJ Leahy, M Stockley, ...
Journal of medicinal chemistry 48 (24), 7829-7846, 2005
Selective Benzopyranone and Pyrimido[2,1-a]isoquinolin-4-one Inhibitors of DNA-Dependent Protein Kinase:  Synthesis, Structure−Activity Studies, and …
RJ Griffin, G Fontana, BT Golding, S Guiard, IR Hardcastle, JJJ Leahy, ...
Journal of medicinal chemistry 48 (2), 569-585, 2005
Small-molecule inhibitors of the MDM2-p53 protein− protein interaction based on an isoindolinone scaffold
IR Hardcastle, SU Ahmed, H Atkins, G Farnie, BT Golding, RJ Griffin, ...
Journal of medicinal chemistry 49 (21), 6209-6221, 2006
Isoindolinone inhibitors of the murine double minute 2 (MDM2)-p53 protein− protein interaction: structure− activity studies leading to improved potency
IR Hardcastle, J Liu, E Valeur, A Watson, SU Ahmed, TJ Blackburn, ...
Journal of medicinal chemistry 54 (5), 1233-1243, 2011
Identification of the major tamoxifen-deoxyguanosine adduct formed in the liver DNA of rats treated with tamoxifen
MR Osborne, A Hewer, IR Hardcastle, PL Carmichael, DH Phillips
Cancer research 56 (1), 66-71, 1996
Characterisation of a Tip60 specific inhibitor, NU9056, in prostate cancer
K Coffey, TJ Blackburn, S Cook, BT Golding, RJ Griffin, IR Hardcastle, ...
Public Library of Science 7 (10), e45539, 2012
N2-substituted O 6-cyclohexylmethylguanine derivatives: potent inhibitors of cyclin-dependent kinases 1 and 2
IR Hardcastle, CE Arris, J Bentley, FT Boyle, Y Chen, NJ Curtin, ...
Journal of medicinal chemistry 47 (15), 3710-3722, 2004
2, 6-disubstituted pyran-4-one and thiopyran-4-one inhibitors of DNA-Dependent protein kinase (DNA-PK)
JJ Hollick, BT Golding, IR Hardcastle, N Martin, C Richardson, ...
Bioorganic & medicinal chemistry letters 13 (18), 3083-3086, 2003
Designing inhibitors of cyclin-dependent kinases
IR Hardcastle, BT Golding, RJ Griffin
Annual review of pharmacology and toxicology 42 (1), 325-348, 2002
Isoindolinone-based inhibitors of the MDM2–p53 protein–protein interaction
IR Hardcastle, SU Ahmed, H Atkins, AH Calvert, NJ Curtin, G Farnie, ...
Bioorganic & medicinal chemistry letters 15 (5), 1515-1520, 2005
Analysis of chemical shift changes reveals the binding modes of isoindolinone inhibitors of the MDM2-p53 interaction
C Riedinger, JA Endicott, SJ Kemp, LA Smyth, A Watson, E Valeur, ...
Journal of the American Chemical Society 130 (47), 16038-16044, 2008
Inhibition of protein prenylation by metabolites of limonene
IR Hardcastle, MG Rowlands, AM Barber, RM Grimshaw, MK Mohan, ...
Biochemical pharmacology 57 (7), 801-809, 1999
Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin down-regulation
M Pennati, AJ Campbell, M Curto, M Binda, YZ Cheng, LZ Wang, N Curtin, ...
Molecular cancer therapeutics 4 (9), 1328-1337, 2005
Cyclin-dependent kinase (CDK) inhibitors: structure–activity relationships and insights into the CDK-2 selectivity of 6-substituted 2-arylaminopurines
CR Coxon, E Anscombe, SJ Harnor, MP Martin, B Carbain, BT Golding, ...
Journal of medicinal chemistry 60 (5), 1746-1767, 2017
Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure− activity relationships for DNA-dependent protein kinase inhibition …
JJ Hollick, LJM Rigoreau, C Cano-Soumillac, X Cockcroft, NJ Curtin, ...
Journal of medicinal chemistry 50 (8), 1958-1972, 2007
Activation of tamoxifen and its metabolite α-hydroxytamoxifen to DNA-binding products: comparisons between human, rat and mouse hepatocytes
DH Phillips, PL Carmichael, A Hewer, KJ Cole, IR Hardcastle, GK Poon, ...
Carcinogenesis 17 (1), 89-94, 1996
Structure-based design of 2-arylamino-4-cyclohexylmethyl-5-nitroso-6-aminopyrimidine inhibitors of cyclin-dependent kinases 1 and 2
KL Sayle, J Bentley, FT Boyle, AH Calvert, Y Cheng, NJ Curtin, ...
Bioorganic & medicinal chemistry letters 13 (18), 3079-3082, 2003
An evaluation of the ability of pifithrin-α and-β to inhibit p53 function in two wild-type p53 human tumor cell lines
MI Walton, SC Wilson, IR Hardcastle, AR Mirza, P Workman
Molecular cancer therapeutics 4 (9), 1369-1377, 2005
The system can't perform the operation now. Try again later.
Articles 1–20